$22.95
0.29[1.28%]
At close: Apr 19
$22.95
0[0.00%]
After Hours: 4:00PM EDT
Corcept Therapeutics
(NASDAQ:CORT)Corcept Therapeutics Stock (NASDAQ:CORT), Analyst Ratings, Price Targets, Predictions
Corcept Therapeutics Inc has a consensus price target of $30.63, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, HC Wainwright & Co., and Canaccord Genuity on February 16, 2024, January 2, 2024, and December 13, 2023. With an average price target of $36 between Truist Securities, HC Wainwright & Co., and Canaccord Genuity, there's an implied 56.86% upside for Corcept Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
HC Wainwright & Co.
Canaccord Genuity
Piper Sandler
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Corcept Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/16/2024 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 83.01% | Truist Securities | Joon Lee | $36 → $42 | Maintains | Buy | Get Alert |
| 01/02/2024 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 22% | HC Wainwright & Co. | Swayampakula Ramakanth | $34 → $28 | Maintains | Buy | Get Alert |
| 12/13/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 65.58% | Canaccord Genuity | Edward Nash | $37 → $38 | Maintains | Buy | Get Alert |
| 11/06/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 65.58% | Truist Securities | Joon Lee | $29 → $38 | Upgrade | Hold → Buy | Get Alert |
| 11/02/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 48.15% | HC Wainwright & Co. | Swayampakula Ramakanth | $32 → $34 | Maintains | Buy | Get Alert |
| 10/02/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 26.36% | Truist Securities | Joon Lee | → $29 | Reiterates | Hold → Hold | Get Alert |
| 08/25/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 52.51% | Canaccord Genuity | Edward Nash | $34 → $35 | Maintains | Buy | Get Alert |
| 08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 35.08% | Piper Sandler | David Amsellem | $27 → $31 | Maintains | Overweight | Get Alert |
| 08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 26.36% | Truist Securities | Gregory Fraser | $26 → $29 | Maintains | Hold | Get Alert |
| 08/03/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 39.43% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $32 | Maintains | Buy | Get Alert |
| 05/26/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 13.29% | Truist Securities | Gregory Fraser | $28 → $26 | Maintains | Hold | Get Alert |
| 05/04/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 30.72% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $30 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 8.93% | SVB Leerink | Roanna Ruiz | → $25 | Initiates | → Market Perform | Get Alert |
| 04/04/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 17.65% | Piper Sandler | David Amsellem | → $27 | Initiates | → Overweight | Get Alert |
| 03/08/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 39.43% | Canaccord Genuity | Edward Nash | $33 → $32 | Maintains | Buy | Get Alert |
| 03/01/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 30.72% | HC Wainwright & Co. | Swayampakula Ramakanth | → $30 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | CORT | Buy Now | Corcept Therapeutics | $22.95 | -4.14% | Jefferies | Dennis Ding | $35 → $22 | Downgrade | Buy → Hold | Get Alert |
| 12/09/2022 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 30.72% | HC Wainwright & Co. | Swayampakula Ramakanth | $33 → $30 | Maintains | Buy | Get Alert |
| 11/08/2022 | CORT | Buy Now | Corcept Therapeutics | $22.95 | 22% | Truist Securities | Gregory Fraser | $30 → $28 | Maintains | Hold | Get Alert |
FAQ
What is the target price for Corcept Therapeutics (CORT)?
The latest price target for Corcept Therapeutics (NASDAQ: CORT) was reported by Truist Securities on February 16, 2024. The analyst firm set a price target for $42.00 expecting CORT to rise to within 12 months (a possible 83.01% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corcept Therapeutics (CORT)?
The latest analyst rating for Corcept Therapeutics (NASDAQ: CORT) was provided by Truist Securities, and Corcept Therapeutics maintained their buy rating.
When was the last upgrade for Corcept Therapeutics (CORT)?
The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.
When was the last downgrade for Corcept Therapeutics (CORT)?
The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Corcept Therapeutics (CORT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
Is the Analyst Rating Corcept Therapeutics (CORT) correct?
While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $36.00 to $42.00. The current price Corcept Therapeutics (CORT) is trading at is $22.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.